NCT05037851 - A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study) | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

November 19, 2021

Primary Completion Date

October 19, 2023

Study Completion Date

November 13, 2023

Conditions

Pulmonary Aspergillosis

Interventions

DRUG

Opelconazole

Nebulizer suspension

DRUG

Standard of Care

Trial Locations (19)

10016

Clinical Research Site, New York

10467

Clinical Research Site, The Bronx

15213

Clinical Research Site, Pittsburgh

19104

Clinical Research Site, Philadelphia

19140

Clinical Research Site, Philadelphia

32224

Clinical Research Site, Jacksonville

33606

Clinical Research Site, Tampa

37232

Clinical Research Site, Nashville

60153

Clinical Research Site, Maywood

63110

Research Site, St Louis

75246

Clinical Research Site, Dallas

77030

Clinical Research Site 1, Houston

Clinical Research Site 2, Houston

Clinical Research Site 3, Houston

85013

Clinical Research Site, Phoenix

90095

Clinical Research Site, Los Angeles

92037

Clinical Research Site, La Jolla

T6G 1Z1

Clinical Research Site, Edmonton

M5G 2N2

Clinical Research Site, Toronto

All Listed Sponsors

lead

Pulmocide Ltd

INDUSTRY